Summary: Guidance on the use of paclitaxel in the treatment of ovarian cancer

This guidance has been partially updated by ‘Paclitaxel, pegylated liposomal doxorubicin hydrochloride and topotecan for second-line or subsequent treatment of advanced ovarian cancer (review)’ (NICE technology appraisal guidance 91 [TA91]).

Recommendations 1.3, 1.4 and 1.5 of TA55 on re-challenge therapy and the second-line treatment of advanced ovarian cancer have been replaced. The recommendations for first-line treatment still stand. See TA91 ( for details of the new recommendations and evidence considered.

This page was last updated: 18 November 2010